Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $7.3 million.

  • Haemonetics' Long-Term Deferred Tax fell 838.75% to $7.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.3 million, marking a year-over-year decrease of 838.75%. This contributed to the annual value of $7.8 million for FY2025, which is 82.7% up from last year.
  • As of Q4 2025, Haemonetics' Long-Term Deferred Tax stood at $7.3 million, which was down 838.75% from $7.6 million recorded in Q3 2025.
  • Haemonetics' 5-year Long-Term Deferred Tax high stood at $9.4 million for Q2 2024, and its period low was $4.3 million during Q4 2022.
  • For the 5-year period, Haemonetics' Long-Term Deferred Tax averaged around $6.4 million, with its median value being $6.1 million (2021).
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first crashed by 2938.65% in 2022, then surged by 9218.46% in 2024.
  • Haemonetics' Long-Term Deferred Tax (Quarter) stood at $6.1 million in 2021, then fell by 20.15% to $4.8 million in 2022, then rose by 4.71% to $5.1 million in 2023, then surged by 57.79% to $8.0 million in 2024, then decreased by 8.39% to $7.3 million in 2025.
  • Its last three reported values are $7.3 million in Q4 2025, $7.6 million for Q3 2025, and $7.8 million during Q2 2025.